Louie, Karly S. and Banks, Victoria and Scholz, Florian and Richter, Hartmut and Ohrling, Katarina and Mohr, Peter and Haferkamp, Sebastian (2020) Real-world use of talimogene laherparepvec in Germany: a retrospective observational study using a prescription database. FUTURE ONCOLOGY, 16 (8). pp. 317-328. ISSN 1479-6694, 1744-8301
Full text not available from this repository. (Request a copy)Abstract
Aim: There is a growing body of data on real-world use of talimogene laherparepvec (T-VEC). We aimed to characterize real-world T-VEC use using a nationally representative German prescription database covering 60% of prescriptions reimbursed. Patients & methods: A retrospective analysis was conducted using the German IMS (R) LRx prescription database, analyzing patients aged >= 18 years with an initial T-VEC prescription at 10(6) plaque-forming units (PFU)/ml and >= 1 subsequent prescription at 10(8) PFU/ml. Median time on T-VEC treatment, patient characteristics and patterns of T-VEC use were described. Results: Of 127 patients prescribed T-VEC, 72 patients (57%) met study criteria. About two-thirds of these patients initiated T-VEC in 2017. Median age at T-VEC initiation was 74 years (range: 44 to 91). Most prescriptions (88%) were dispensed from hospitals. At study end, 26 (36%) patients remained on T-VEC; 46 (64%) had ended treatment. Median duration of T-VEC treatment for all patients was 18.7 weeks (95% CI: 15.3-26.9) and was longer among those who initiated treatment in 2017 versus 2016 (26.7 vs 15.6 weeks, respectively). Median volume administered for the first 10(6) PFU/ml and second 10(8) PFU/ml was 4 ml; the volume decreased for subsequent administrations (2 ml by the eighth administration and 1 ml by the 16th administration). Conclusion: This real-world prescription database study showed that patients who initiated treatment in 2017 had a treatment duration in clinical practice that corresponded with the European Summary of Product Characteristics guideline of continuing T-VEC for >= 6 months. Additional long-term data linking drug use with clinical outcomes are needed.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | HERPES-SIMPLEX-VIRUS; MELANOMA; SAFETY; Germany; immunotherapy; melanoma; prescription; real-world; retrospective; talimogene laherparepvec; T-VEC |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Dermatologie und Venerologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 29 Mar 2021 10:11 |
| Last Modified: | 29 Mar 2021 10:11 |
| URI: | https://pred.uni-regensburg.de/id/eprint/44981 |
Actions (login required)
 |
View Item |
